Safety, immunogenicity, and efficacy of a recombinantly produced plasmodium falciparum circumsporozoite protein-hepatitis b surface antigen subunit vaccine

Journal of Infectious Diseases

Volumn 171, Issue 6, 1995, Pages 1576-1585

  Gordon, D M ^a,b,c,d   Mc Govern, T W ^a,b,c,d   Krzych, U ^a,b,c,d   Cohen, J C ^a,b,c,d   Schneider, I ^a,b,c,d   La Chance, R ^a,b,c,d   Heppner, D G ^a,b,c,d   Yuan, G ^a,b,c,d   Hollingdale, M ^a,b,c,d   Slaoui, M ^a,b,c,d   Hauser, P ^a,b,c,d   Voet, P ^a,b,c,d   Sadoff, J C ^a,b,c,d   Ballou, W R ^a,b,c,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PHOSPHORYL LIPID A; PROTOZOAL PROTEIN;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA FALCIPARUM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; CYTOTOXICITY, IMMUNOLOGIC; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0029057169     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.6.1576     Document Type: Article

References (25)

1. Rutgers T, Gordon DM, Gathoye AM, Hockmeyer WT, De Wilde M, Rosenberg M. Hepatitis B surface antigen as a carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Biotechnology 1988;6:1065-70.
2. Vreden SG, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 1991;45:533-8.
3. Jacobs E, Rutgers T, Voet P, Dewerchin M, Cabezon T, de Wilde M. Simultaneous synthesis and assembly of various hepatitis B surface proteins in Saccharomyces cerevisiae. Gene 1989;80:279-91.
4. Wirtz RA, Ballou WR, Schneider I, et al. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol 1987;63:166-72.
5. Egan JE, Hoffman SL, Haynes JD. etal. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporo- zoites. Am J Trop Med Hyg 1993;49:166-73.
6. Hollinger FB, Troisi CL, Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis 1986; 153:156-9.
7. Hollingdale MR, Nardin EH, Tharavanij S, Schwanz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporo- zoites into cultured cells; an in vitro assay of protective antibodies. J Immunol 1984;132:909-13.
8. Houghten RA. General method for the rapid solid-phase synthesis of large number of peptides: specificity of antigen-antibody interactions at the level of individual amino acids. Proc Natl Acad Sei USA 1988;85:1199-203.
9. Chulay JD, Schneider 1, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986;35:66-8.
10. White K, Krzych U, Gordon DM, et al. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. Vaccine 1993;11:1341-6.
11. Brown AE, Webster HK, Gross M, Permpanich B, Gordon DM. Characterization of naturally acquired antibodies to the non-repctitive flanking regions of the circumsporozoite protein of Plasmodium falciparum. Am J Trop Med Hyg 1992;47:440-5.
12. Calle JM, Nardin EH, Clavijo P, et al. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers. J Immunol 1992; 149:2695-701.
13. Hoffman SL, Franke ED, Rogers WO, Mellouk S. Preerythrocytic malaria vaccine development. Molecular immunological considerations. In: Good MF, Saul AJ, eds. Malaria vaccine development. Boca Raton, FL: CRC Press, 1993:149-67.
14. Good M, Maloy WL, Lunde MN, et al. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 1987;235:1059-62.
15. Good MF, Pombo D, Quakyi IA, et al. Human T-cell recognition protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988;85:1199-203.
16. Malik A, Egan JE, Houghten RA, Sadoff JC. Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodium falciparum circum- sporozoite protein. Proc Natl Acad Sci USA 1991;88:3300-4.
17. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992;89:358-62.
18. Hoffman SL, Edelman, Bryan JP, et al. Safety, ¡mmunogenicity, and efficacy of a malaria sporozoite vaccine administered with mono- phosphoryl lipid A, cell wall skeleton of mycobacteria, and squalene as adjuvant. Am J Trop Med Hyg 1994;51:603-12.
19. Sadoff JC, Ballou WR, Baron LS, et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988;240:3360-8.
20. Romero P. Maryanski JL, Corradin G, Nusscnzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989;341:323-6.
21. Ribi E, Cantrell J, Feldner T, et al. Biological activities of monophosphoryl lipid A. In: Levine L, Bonventre PF, Morello JA, et al., eds. Microbiology. Washington. DC: American Society for Microbiology, 1986.
22. Myers KR, Truchot AT, Ward J, et al. A critical determination oflipid A endotoxin activity. In: Nowotny A, ed. Cellular and molecular aspects of endotoxin reactions. Proceedings of the 1st Congress of the International Endotoxin Society. Amsterdam: Elsevier. 1990:145- 56.
23. Loppnow H, Durrbaum I, Brade H, et al. Lipid A, the immunostimulatory principle of lipopolysaccharides. In: Friedman H, Klein TW, Nakano M, eds. Advances in experimental medicine and biology. Voi 256. New York: Plenum Press, 1990:561-6.
24. Johnson AG, Tomai MA. A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A. In: Friedman H, Klein TW, Nakano M. eds. Advances in experimental medicine and biology. Voi 256. New York: Plenum Press, 1990:567-79.
25. Kimball JH. Introduction to immunology. New York: MacMillan, 1986:78.